HD17 for Intermediate Stage Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Keywords

Hodgkin Lymphoma, intermediate stage, PET

Brief summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

Lommen M, Weindler JJ, Jablonski J, Rosenbrock J, Borchmann P, Behringer K, Roth KS, Ufton D, Dietlein M, Kobe C, Ferdinandus J.

2025-10-11

10.1007/s00259-025-07569-5

Prognostic value of baseline metabolic tumor volume (<scp>MTV</scp>) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase <scp>III HD17</scp> trial

Lutz van Heek, Jasmin Weindler, Claudia Gorniak, Helen Kaul, Horst Müller et al. (14 authors)

European Journal Of Haematology2023-08-2910 citations

10.1111/ejh.14093

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A.

2021-02-0195 citations

10.1016/s1470-2045(20)30601-x

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

Conrad‐Amadeus Voltin, Helen Goergen, Christian Baues, Michael Fuchs, Jasmin Mettler et al. (14 authors)

Annals of Oncology2018-07-1356 citations

10.1093/annonc/mdy250

Interventions

DRUGBEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)

DRUGABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)

RADIATION30Gy IF-RT (Involved-Field Radiotherapy)

RADIATION30Gy IN-RT (Involved-Node Radiotherapy)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

No

Inclusion criteria

* Hodgkin Lymphoma * CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included) * large mediastinal mass (\>1/3 of maximum transverse thorax diameter) * extranodal involvement * elevated ESR * 3 or more involved nodal areas * written informed consent

Exclusion criteria

* Leucocytes \<3000/µl * Platelets \< 100000/µl * Hodgkin Lymphoma as composite lymphoma * Activity Index (WHO) \>2

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	3 years

Secondary

Measure	Time frame	Description
Overall Survival	3 years	—
CR rate	6 months	Rate of patients achieving a complete remission (CR/CRu) at final restaging after completion of study treatment

Countries

Germany

Outcome results

None listed